Advertisement
Screener

ENDONOVO THERAPEUTICS, INC. (ENDV) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances

2.8 / 5 stars · 68/120 Roast Me

ENDONOVO THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances

ENDONOVO THERAPEUTICS, INC. (ENDV) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $1.24 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-04-14.

Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)

us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2022-04-14

  • ENDONOVO THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2020 was $1.24M.
Period endFair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month
2020-12-31$1.24M
10-K · filed 2022-04-14